U ntil the 1990s, the adult mammalian brain was considered a postmitotic organ. It is primarily composed of mature, specialized neurons with trillions of synaptic connections, along with mature glia. Hence, it was widely accepted that malignant gliomas arose from differentiated CNS cells 1 . More recent appreciation of the existence and importance of neural stem cells in the mature brain has prompted a revisiting of the potential source(s) of glioma and the scope of adult cell types along the neuronal lineage that have tumor potential.
1
. More recent appreciation of the existence and importance of neural stem cells in the mature brain has prompted a revisiting of the potential source(s) of glioma and the scope of adult cell types along the neuronal lineage that have tumor potential.
In the adult rodent brain, the most abundant neural stem cell niches reside in the subventricular zone (SVZ) of the lateral ventricles and the subgranular layer of the hippocampal dentate gyrus. Stem cells divide symmetrically to self-renew and perpetuate the stem cell pool throughout the lifetime of an organism. They also divide asymmetrically to give rise to progenitor cells with more restricted self-renewal potential. Adult neural progenitor cells undergo several rounds of cell division before producing newly born immature neurons, or neuroblasts, that further differentiate into specialized neuronal cell types [2] [3] [4] . A variety of glioblastoma mouse models have been developed using disease-relevant initiating mutations in tumor suppressors (for example, Pten, Trp53, Nf1, Cdkn2a (Ink4a/Arf) and Rb1) and oncogenes (for example, EGFRvIII and Pdgfra) 5 . Our previous studies used a Nestin promoter-driven cre-recombinase estrogen-receptor ligand binding domain (LBD)-T2 fusion Nestin-creER T2 transgene that specifies expression in adult neural stem and progenitor cells to drive Nf1, Trp53 and Pten deletion and development of high-grade gliomas with 100% penetrance 6 . Also, Ascl1-creER TM (Ascl1-driven cre-recombinase estrogen-receptor LBD-TM fusion), which targets adult bipotential (neural and oligodendrocyte) progenitors, and the adult oligodendrocyte progenitor cell (OPC)-specific NG2 (Cspg4)-creER TM , can drive glioblastoma 7, 8 . In vivo ablation of Pten, Trp53 and Rb1 with a Gfap-creER TM transgene expressed in quiescent neural stem cells as well as mature astrocytes led to the induction of high-grade gliomas in close proximity to the neurogenic niches, adding experimental support for a stem cell origin 9 . Studies that target nonadult cells such as embryonic and early-postnatal stem and progenitor cells by viral transduction, transplantation or genetic methods have also produced similar results 10 . Dedifferentiation has also been proposed as a pathway to gliomagenesis. Cultured early postnatal 'astrocytes' overexpressing EGFR together with deletion of Ink4a/Arf developed tumors when transplanted into immunodeficient mice 11 . However, it is unclear whether proliferative postnatal day 5 neonatal astrocytes faithfully represent in vivo mature adult astrocytes that lack progenitor properties. Injections of a constitutive H-RasV12 or short hairpin RNA-expressing lentivirus targeting Nf1, together with Trp53, into brains of adult mice induce gliomas in mature neurons 12 . In these studies, oncogenic Ras, or Nf1 and Trp53 knockdowns, were induced broadly, mediated by the H1 and U6 promoters, thus confounding precise analysis of tumor cell of origin.
In this study, we targeted the glioblastoma-associated tumor suppressors Nf1, Trp53 and Pten at progressive stages of adult neural differentiation. Regardless of the cell lineage targeted, we identified molecular and phenotypic evidence of tumor suppressor loss. However, in contrast to the fully penetrant glioblastoma phenotype observed when stem cells or early progenitors were targeted, more differentiated neuronal cells showed reduced defects, demonstrating that increasing lineage restriction is an impediment to glioma formation. gene is expressed in mature excitatory neurons in the adult cortex, hippocampus and striatum 14 , and its regulatory elements have been used to drive transgene expression with fidelity 15, 16 . We used Camk2a-creER T2 to target adult, postmitotic differentiated neurons and confirmed transgene activity and expression by X-gal staining of Camk2a-creER T2 ;R26-stop-LacZ reporter mice induced with tamoxifen at 4 weeks of age and examined 4 weeks later (Fig. 1a,b) . Cre-recombined cells were observed in the cortex and hippocampus, with scattered staining in the striatum, thalamus and cerebellum. We confirmed recombination in specific cell types by double immunofluorescence staining of the β-galactosidase reporter with cell lineage-specific antibodies including NeuN to stain mature neurons but not the astroglial marker glial fibrillary acidic protein (Gfap) or the oligodendroglial marker adenomatous polyposis coli or Apc (Fig. 1c) . In addition, the Camk2a-creER T2 ;R26-stoptdTomato reporter was localized to mature neurons and did not show colocalization with immature markers Doublecortin, Nestin, Sox2 or Olig2 (Fig. 1c) ). Mice were induced with tamoxifen at 4-8 weeks of age along with controls (iCK-cre-negative tumor suppressor conditional mice administered tamoxifen or iCK-crepositive tumor suppressor conditional mice administered vehicle (sunflower oil)). iCK-cre mutants appeared indistinguishable from wild-type controls and did not exhibit overt developmental or behavioral abnormalities. We confirmed cre-mediated recombination in aged mice by X-gal staining, which showed retention of β-galactosidase-positive recombined cells, particularly in the cortex and hippocampus in mutants (Fig. 1d) .
Because the targeted mice did not show adverse symptoms, we performed sequential analysis of mutant brains at different times. Hematoxylin and eosin (H&E) staining of iCK-cre mutants over 18 months indicated morphologically normal brains with no overt neurological deficits (Fig. 1e) . We confirmed tumor suppressor loss by analysis of DNA from microdissected hippocampi and cortices, and polymerase chain reaction (PCR) genotyping showed the presence of Cre and recombined conditional alleles in Cre + mutant versus Cre -control brains (Fig. 1f , data not shown). Kaplan-Meier analysis showed similar survival between iCK-cre mutants and controls (P > 0.9999; Fig. 1g ). Hence, deletion of glioblastomaassociated tumor suppressors in adult mature neurons led to asymptomatic mice lacking evidence of glioma formation.
We found no evidence of abnormal proliferation in all iCK-cre mutant brain regions examined after short-term BrdU (5-bromo-2´-deoxyuridine) pulses or by Ki67 immunohistochemistry (Fig. 2a) . Apoptosis measured by cleaved caspase 3 immunohistochemistry also showed no difference between mutant and control (data not shown). However, iCK-cre mutant brains showed abnormal features reflective of signaling pathway alterations. Notably, areas of reactive astrogliosis, evidenced by intense Gfap staining, were present in both young and aged mutant mice (Fig. 2a,b) . This phenomenon is reminiscent of the Synapsin1 (Syn1)-cre;Nf1 flox/flox phenotype, which showed global non-cell autonomous astrogliosis 17 , and probably reflects a paracrine reactive astrocytic response to neuronal loss of tumor suppressors.
Examination of histologic and morphometric features of aged tumor suppressor-deficient neurons showed increased soma size as compared to controls, particularly in the cortex and dentate gyrus (Fig. 2c-e) . Nissl staining showed neuronal hypertrophy, with deep staining in mutant brains (Fig. 2c) that was confirmed by NeuN immunohistochemistry (Fig. 2d,e and Supplementary  Fig. 1a ). We found increased Map2 staining, whereas other specialized neuronal markers were not significantly altered (Fig. 2d,e and Supplementary Fig. 1b) . Some of these neuronal defects are similar to the previously described phenotype of Pten-deficient neurons 18 . Additional analyses including shallow whole-genome sequencing and telomere fluorescence in situ hybridization (FISH) showed evidence of increased chromosomal abnormalities and telomere elongation, respectively (Fig. 2f, Supplementary  Fig. 1c-e and Supplementary Table 1) . Overall, these aging experiments showed no evidence of tumor formation or preneoplastic lesions in iCK-cre mutants.
Mutant immature neurons exhibit abnormal proliferation. In the adult SVZ, neural stem cells serve as a continuous source of new neurons by forming amplifying progenitor cells that produce neuroblasts, which typically undergo one to two cell divisions 4, 19 . To determine whether adult, immature neurons can undergo tumorigenesis, we used the Neurod1-creER T2 transgene 20 . Analysis of Neurod1-creER T2 ; R26-stop-tdTomato reporter mice verified transgene coexpression with the immature neuronal marker Doublecortin, especially in the olfactory bulb granular cell layer and striatum, as well as dentate gyrus and cortex (Fig. 3a-c and Supplementary Fig. 2a,b) . The Tomato reporter was also coexpressed with the more differentiated marker NeuN, but not with the early progenitor markers Sox2, Olig2, Gfap or Nestin ( Fig. 3c and Supplementary Fig. 2b ).
Neurod1-creER T2 (hereafter called iND-cre) mutants were bred to contain the tumor suppressor conditional alleles (iND-cre;Nf1 ) and induced at 4-8 weeks of age. We confirmed cre-mediated recombination by PCR genotyping ( Fig. 3d ; data not shown). As early as 10 weeks after tamoxifen induction, we found increased BrdU incorporation in iND-cre mutants ( Supplementary Fig. 2c ), which persisted in older mice (Fig. 3e,f and Supplementary Fig. 2d ). A proportion of the iND-cre mutants developed masses outside the brain, probably owing to transgene expression in the peripheral nervous system, including cranial and dorsal root ganglia 20 , and other tissues such as muscle; these mice were prematurely killed ( Fig. 3g ; data not shown). However, the cohort of mutant mice that survived 11 months or more showed no evidence of glioma formation (Fig. 3e,g,h) . We observed astrogliosis and increased BrdU + cells in older iND-cre mutants, phenotypes that appeared to be transient in nature, as no appreciable intracranial masses, histologic abnormalities or differences in expression of other lineage markers developed (Fig. 3e ,f,h and Supplementary Fig. 2d,e) . Thus, tumor suppressordeficient immature neurons exhibit extended cell division but no obvious histologic abnormalities, and remain incapable of undergoing frank transformation and tumorigenesis.
Neuronal progenitor targeting causes hyperplastic defects.
Having established the inability of adult mature and immature neurons to initiate glioma in response to tumor suppressor ablation, we next moved upstream in the progenitor pathway to late-stage neuronal progenitors. We used a Dlx1-creER T2 knock-in mouse (hereafter called iDlx-cre) to specifically target tumor suppressors in adult neuronal progenitors 21 . Neural stem cell cultures derived from SVZ of iDlx-cre mice have previously been shown to produce neurospheres when grown in serum-free conditions 22 , and the transgene has been used to study developing progenitors and GABAergic interneurons 21 . We confirmed cre activity in adult neuronal progenitors using the iDlx-cre;R26-stop-tdTomato reporter by tamoxifen induction at 4-8 weeks of age. Examination at 1 month and 5 months after tamoxifen induction showed expression in the dentate gyrus, particularly in the granule cell layer, the glomerular layer in the olfactory bulb, and the cortex and cerebellum 
Tamoxifen induction (iCK-cre) construct. Right, timeline of tamoxifen induction and analyses of reporter and mutant strains. b, X-gal staining of tamoxifen-versus vehicle-induced iCK-cre;R26-stop-LacZ reporter 1 month after induction (i,i´, whole brain; ii,ii´, cortex (ctx); iii,iii´, higher magnification of cortex; iv,iv´, hippocampus (hp); v,v´, dentate gyrus (dg); vi,vi´, higher magnification of dentate gyrus; vii,vii´, olfactory bulb (ob); viii,viii´, striatum (str); ix,ix´, thalamus (thl); x,x´, cerebellum (cbm). Scale bars: i,i´, 2 mm; ii,ii´ to x,x´, 100 μm. c, Immunofluorescence staining of iCK-cre reporters 1 month after induction. Top, immunostaining of iCK-cre;R26-stop-LacZ reporter brain sections using β-galactosidase and cell type-specific markers NeuN (neurons), Gfap (astrocytes) and Apc (oligodendrocytes). Bottom, immunostaining of iCK-cre;R26-stop-tdTomato reporter brain sections with Tomato and lineage markers NeuN, Dcx (Doublecortin), Gfap, Nestin, Sox2 and Olig2. Scale bars, 100 μm. d, X-gal staining of iCK-cre mutant versus control 12 months after induction. Scale bars, 100 μm. e, H&E staining of iCK-cre mutants versus controls at 6 months and 13 months postinduction (6 mo and 13 mo p-i, respectively). Scale bars, 100 μm. f, Genotyping for Cre and recombined, loxP (flox) and wild-type (WT) alleles of Nf1, Trp53 and Pten (right) using microdissected mutant (MUT) and control (CON) brain regions (left). Scale bars, 2 mm. g, Survival curve of iCK-cre mutants (n = 19) versus controls (n = 11). P > 0.9999 using log-rank (Mantel-Cox) test. Arrows show n = 5 asymptomatic mutant mice that were killed for analysis 5-9 months after tamoxifen induction for nonhealth-related reasons. In b-f, experiments were independently repeated with similar results at least n = 3 times using at least n = 3 different mouse tissue samples for each group. Fig. 4c and Supplementary Fig. 3b ). Thus, iDlx-cre activity is confined to advanced-stage neuronal progenitors.
We bred iDlx-cre to contain the tumor suppressor conditional alleles (iDlx-cre;Nf1 Map2 + mean signal intensity (AFU)/NeuN + cells C o n t r o l M u t a n t C o n t r o l M u t a n t + mean signal intensity per NeuN + cell number in iCK-cre mutants (n = 9) versus controls (n = 9). P = 0.0082. *P < 0.05, **P < 0.01 using two-tailed unpaired Student's t test. Data are presented as mean ± s.e.m. f, Shallow whole-genome sequencing of iCK-cre mutants (n = 3) compared to controls (n = 3). Chromosomal segmentation analysis of mutant recombined brain regions (top two panels) and a Syn1-cre mutant tumor positive control (bottom panel) showing log ratio of normalized counts between mutant and control on y axis and probe index on x axis. All scale bars, 100 μm. In a,c,d, experiments were independently repeated with similar results at least n = 3 times using at least n = 3 different mouse tissue samples for each group.
abnormal SVZ and rostral migratory stream (RMS) proliferation beginning at 10 weeks after induction (Fig. 4e) . We also observed increased Gfap staining in these regions and shortened life spans (Fig. 4f) . Despite the evident abnormal brain proliferation and hyperplasia observed from 6 months to >1 year after tamoxifen induction (Fig. 5a-c and Supplementary Fig. 4a ), careful brain pathology surveys did not identify evidence of intracranial tumors (Fig. 5c) . The Dlx1 gene is expressed outside the brain, including in muscle and endocrine glands (www.proteinatlas.org). Probably related to this non-CNS expression, a small subset of mutant mice exhibited limb paralysis and tumors in the head and extremities. Histologic analysis of extracranial tumors from both iDlx-cre and iND-cre mice show high expression of smooth muscle actin and desmin, consistent with a mesenchymal origin 23 (data not shown). However, the dominant cohort of mutant mice that were aged more than 1 year after tamoxifen induction showed no evidence of intracranial tumor formation.
In addition, iDlx-cre mutants showed increased CNS expression of the progenitor markers Sox2, Nestin and Doublecortin ( Fig. 5a and Supplementary Fig. 4b ). The evidence for persistent progenitor proliferation in the absence of tumor development can be explained by constant apoptosis, sustained differentiation, or some combination of the two. We did not observe increased apoptosis as measured by cleaved caspase 3 staining, whereas long term BrdU pulse chases showed BrdU + cell migration into the olfactory bulb (data not shown). Thus, tumor suppressor targeting of adult neuronal progenitors elicits histologic and proliferative abnormalities reminiscent of the pretumorigenic state observed in previous glioma models 6, 7, 24 . The molecular pathways linked to p53, Nf1 and Pten are not confined to cell proliferation or survival. The Ras-Nf1 and . P = 0.0253. *P < 0.05 using two-tailed unpaired Student's t test. Data are presented as mean ± s.e.m. g, Kaplan-Meier survival curve of iND-cre mutants (n = 16) versus controls (n = 13). P = 0.0493 using log-rank (Mantel-Cox) test. h, H&E staining of aged iND-cre mutant versus control mouse brains. Scale bar, 100 μm. In b-e,h, experiments were independently repeated with similar results at least n = 3 times using at least n = 3 different mouse tissue samples for each group.
phosphatidyl-inositol-3-kinase (PI3K)-Pten pathways impinge on many effectors of cellular function including migration, cytoskeletal remodeling, metabolism, endocytosis and autophagy. p53 not only serves as a cell cycle check point but also mediates many cellular stress responses including DNA damage and senescence 25 . To verify that tumor suppressor loss elicited downstream effectors, we examined specific molecular events in mutant brains.
Western blotting for γ-H2AX showed increased DNA damage in the dentate gyrus of iDlx-cre mutant neurons (Fig. 5d ) and confirmed elevated p-Erk and p-Akt (Supplementary Fig. 4c ). Both iDlx-cre and iCK-cre mutants showed increased expression of senescence marker p27 ( Fig. 5d ; data not shown). We did not observe changes in p16 or p21, nor in markers of autophagy (Lc3b or p62) or senescence-associated secretory phenotype (SASP) ( Fig. 5d ; data not shown), whereas telomere FISH showed shorter telomeres in iDlx-cre mutants ( Supplementary Fig. 4d-f) . Thus, cells of the neuronal lineage targeted by iDlx-cre and iCK-cre exhibit multiple pathway abnormalities consequent to tumor suppressor loss without eliciting tumor development.
Ectopic Syn1-cre expression drives glioblastoma formation. In this study, we also examined tumor suppressor recombination mediated by a Syn1-cre transgene. Syn1-cre becomes active in the developing CNS at embryonic day 13.5 (E13.5) and has been previously employed to study the function of the Nf1 gene in neurons, under conditions that required predominant but not absolute or exclusive expression in neurons 17 . In the present scenario where, as for iCK-cre, exclusive mature neuronal recombination was intended, a detailed analysis of Syn1-cre expression was performed using the tdTomato reporter. Although, as previously documented 17 , a majority of Tomato + cells colabel with the neuronal marker NeuN, we found that a substantial subset of Tomato + cells also marked both oligodendrocyte and neural progenitors, as well as astrocytes in the adult brain. Tomato + cells colabeled with the oligodendrocyte progenitor marker Olig2 and the neural progenitor marker Sox2, particularly in the cortex near the corpus callosum border, and with Gfap + cells elsewhere in the brain, including the dentate gyrus ( Fig. 6a ; data not shown). Thus, the Syn1-cre transgene has unexpected nonneuronal expression in adult CNS progenitors. When Syn1-cre was bred to contain various configurations of the Nf1, Trp53 and Pten conditional alleles (Syn1-cre;Nf1 ), mutant mice that were homozygous for both Nf1 and Trp53 exhibited shortened lifespans compared to mutants that were heterozygous for both or all three alleles (Fig. 6b) . Double-knockout mice (Syn1-cre;Nf1 ) did not develop tumors nor did they exhibit proliferative defects (Fig. 6c,d) . However, ), however, developed tumors starting at 5 months of age (Fig. 6b) . These tumors showed histologic features of glioblastoma, with expression of the glioblastoma markers Gfap, Ki67, Olig2, Sox2 and Pdgfrα, and with some cells positive for NeuN (Fig. 6e) . We confirmed that these tumors arose from cre-mediated recombination by X-gal staining, PCR genotyping and immunostaining ( Fig. 6f; data not shown) .
We have previously shown that adult OPCs can give origin to glioblastoma with characteristic cellular, histologic and molecular features (type 2) that are distinct from those derived from adult neural stem cell-driven Nestin-creER T2 mutants (type 1) 7, 8 . Syn1-cre tumors exhibit striking similarities to type 2 glioblastoma, including well-defined borders indicative of low infiltration, high Olig2 and Pdgfrα and reduced Gfap expression, with preferential location in the ventral brain. These data, taken together with the iCK-cre studies, raise the possibility that Syn1-cre-induced glioblastoma does not originate in neurons. When we compared the transcriptional profiles of Syn1-cre tumors with that of type 1 (Nestin-creER T2 ) and type 2 (NG2-creER TM ) tumors by RNA sequencing, Syn1-cre tumor profiles preferentially clustered with type 2 tumors and showed enrichment for the NG2-creER TM glioblastoma signature, including expression of genes associated with the oligodendrocytic lineage (Fig. 6g, Supplementary Fig. 5 and Supplementary Table 2 ). The present data, taken as a whole, provide support for the contention that the tumor cell of origin for Syn1-cre-derived glioblastoma is the OPC lineage and not mature neurons.
Discussion
The rodent brain is composed of >300 million cells with approximately 60% neurons and 40% glia, in addition to many essential, non-CNS-specific resident cells 26 . In contrast, the pool of adult stem and progenitor cells comprises a minimal fraction of CNS cells. Glioblastoma is the most common adult primary brain malignancy and historical thinking based on anecdotal evidence and histologic associations conferred the origin of these tumors to astrocytes 1 . The advent of genetically engineered mouse models prompted revisiting of this issue, and the data has increasingly implicated CNS stem cells and their early progeny as the most probable source of glioblastoma 6, 7, 24, 27 . Our previous studies provide indirect evidence for the reduced tumorigenic capacity of non-stem or progenitor cells. Here, we directly address the tumorigenic potential of increasingly differentiated CNS neuronal lineage cells by using well-characterized conditional Cre recombinase driver transgenes. The data show that deletion of three of the most commonly mutated tumor suppressors in human glioblastoma can be effectively accomplished in each of the targeted cell types. In contrast to the 100% glioblastoma incidence elicited in neural stem cells, the phenotypic consequences of tumor suppressor deletion in more differentiated cells were insufficient to drive glioblastoma formation. Taken together with studies associating stem cells and early progenitors with glioblastoma, these data indicate an inverse relationship between glioblastoma-initiating potential and differentiation state of neuronal cell types, where stem cells are most susceptible and mature neurons the most resistant to malignant transformation (Fig. 7) . The glioblastoma cell-oforigin hierarchy shares similarities with that of leukemias, in which mutations may accumulate in long-lived hematopoietic stem cells or confer self-renewal capacity to specific progenitor populations 28 . Our studies demonstrate that tumor suppressor-deficient cells beyond the early progenitor state are phenotypically altered despite not undergoing malignant transformation. Better insight into the mechanisms that prevent more differentiated cells from re-entering the cell cycle could advance our understanding of intrinsic cellular anticancer barriers.
Contrary to the present results, it has been reported that mature neurons can undergo dedifferentiation to give rise to glioblastoma 12 .
Mouse models of brain tumors were generated using stereotactic injection of lentiviruses expressing either oncogenic Ras or short Tom Sox2 P7 1 mo hairpin RNAs to Nf1 together with Trp53 under nonspecific promoters and using the Syn1-cre transgene as an independent reporter for neurons. Our present results demonstrating Syn1-cre transgene expression in OPCs and neural progenitors that are known cells of origin for glioblastoma 7 broaden the scope of interpretation of the preceding studies, raising the possibility that these tumors did not arise from dedifferentiation of mature neurons 12 .
We selected mutations in TP53, NF1 and PTEN by virtue of their inclusion in a large proportion of human glioblastoma 13 ; these are also the same mutations used in previous studies described 12, 29 . Our data do not address whether other classes and combinations of mutations would render differentiated neurons tumorigenic. Compelling studies have demonstrated that a Ras oncogene can render astrocytic cells tumorigenic in an experimental setting 30 . However, Ras mutations are exceedingly rare in the repertoire of glioblastoma mutations, making it improbable that those conditions would occur in a physiologic setting 13 . Reports of reprogramming of neurons into stem cells have used early postnatal neuronal cultures with the Yamanaka factors (Oct3/4, Klf4, Sox2 and c-Myc) and involved concurrent p53 suppression and overexpression of repressor element-1 repressing transcription (REST), illustrating the difficulty of forcing these cells to re-enter the cell cycle, even in this extremely artificial in vitro setting 31 . However, it is possible that other oncogenic mutations and other tumor suppressor combinations not tested here have the capacity to transform differentiated cell types. In leukemia, different cells along the hematopoietic lineage were shown to harbor differential sensitivities to specific oncogenic mutations 32 . Depending on the model system used, MLL-AF9 mutations transform committed progenitors, whereas others such as BCR-ABL are oncogenic only when expressed in stem cells 32 . Hence, the identity of the cell of origin, which is also related to the developmental stage and intrinsic properties of the cell lineage, is as important as the initiating event.
The present data implicate a small fraction of cells in the brain with glioblastoma potential. The relative paucity of transformable cells in the brain as compared to epithelial organs such as lung or colon may contribute to the much lower incidence of CNS tumors compared to other cancer types. These theories have been supported by studies that suggest that cancer incidence is proportionally related to the size of the stem cell pool 33 . Indeed, many reports have recorded the presence of neural stem cells in the adult human brain 34 . However, recent controversy has arisen from contrasting reports regarding the relative abundance of adult human neural stem cells. One report has claimed complete decline in progenitor populations in the adult human CNS 35 , whereas another has shown persistent neurogenesis, albeit with decline, throughout life 36 . Examples of robust adult neurogenesis in other species including the seasonal maturation of high vocal center CNS nuclei in songbirds, as well as SVZ and hippocampal neurogenesis in rodents 3, 4 , primates 37 and humans 38 , challenge the notion that neurogenesis would disappear in the most advanced stages of CNS evolution. Along these lines, a recent report using whole-exome and single-cell sequencing of matched glioblastoma patient brain tissue has shown a lineage relationship in tumor evolution arising from SVZ cells with low-level driver mutations 39 . These recent findings, together with our current and previous data 6, 7, 24, 27 , are most consistent with a stem or progenitor cell of origin for glioblastoma, whereas dedifferentiation from postmitotic neurons or neuroblasts is a less probable event.
The incidence of cancer increases proportionally with age. For a solid tumor to arise, a single tumor cell of origin must accumulate a cohort of oncogenic and tumor-suppressive driver mutations. These requirements are consonant with the notion that self-renewing stem cells or closely related progeny are a more plausible source of tumors compared to postmitotic cells. These self-renewing cells retain cell cycle activity over prolonged periods, albeit with reduced frequency, allowing for sequential accumulation of mutations over time. Moreover, the mechanisms involved in causing functional transformation of a stem cell into a tumor seem less constraining than those envisioned to force a terminally differentiated cell to overcome the transcriptional and epigenetic barriers that govern specialized function, as differentiated cells have innate programs to prevent cell cycle re-entry. Accordingly, many studies have explored the possibility of differentiation therapy to inhibit tumor cell proliferation, and a few examples already exist in a clinical setting 40, 41 . Understanding these antitumorigenic mechanisms may continue to reveal effective anticancer therapeutic targets, especially for glioblastoma and other fatal cancers.
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